Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 3970722)

Published in J Multidiscip Healthc on March 03, 2014

Authors

Byron Cryer1, Kenneth W Mahaffey2

Author Affiliations

1: University of Texas Southwestern Medical School, Dallas, TX, USA.
2: Department of Medicine, Stanford University, Stanford, CA, USA.

Articles cited by this

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (2002) 20.22

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64

Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med (1991) 10.55

JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart (2005) 9.79

ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation (2004) 7.72

Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2009) 7.34

The burden of selected digestive diseases in the United States. Gastroenterology (2002) 6.79

Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet (2002) 5.58

Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ (1995) 4.50

Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet (1996) 4.21

Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med (2009) 3.90

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med (2002) 3.84

Management of patients with ulcer bleeding. Am J Gastroenterol (2012) 3.60

Peptic ulcer disease. Lancet (2009) 3.23

Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA (2005) 3.19

Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. BMJ (1994) 3.18

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med (2001) 3.02

Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med (1991) 2.98

Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ (1996) 2.90

2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2012) 2.88

Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet (1996) 2.75

Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol (2009) 2.73

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2008) 2.67

Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J (2004) 2.42

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation (2008) 2.40

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut (2006) 2.02

Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol (2008) 1.99

Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med (2000) 1.96

Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med (2005) 1.91

Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol (2008) 1.89

2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 1.87

Peptic ulcer disease. Am Fam Physician (2007) 1.73

Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med (1980) 1.72

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation (2010) 1.69

Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med (2006) 1.62

Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med (1988) 1.58

Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv (2011) 1.56

Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation (1998) 1.51

Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol (2010) 1.51

Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin (2007) 1.44

Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol (1995) 1.42

Triple antithrombotic management after stent implantation: when and how? Heart (2009) 1.42

Helicobacter pylori management in non-steroidal anti-inflammatory drug therapy patients in primary care. Intern Emerg Med (2011) 1.40

Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther (2002) 1.38

Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther (2002) 1.33

Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther (2005) 1.32

Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol (2001) 1.30

National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology (2005) 1.29

Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control (2002) 1.28

Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J (2005) 1.26

Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol (2012) 1.24

Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation (2010) 1.20

Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol (1991) 1.08

Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart (2011) 1.06

Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med (2008) 1.03

Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J (2009) 1.03

Risk factors for gastrointestinal bleeding associated with low-dose aspirin. Best Pract Res Clin Gastroenterol (2012) 1.02

Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem Pharmacol (2001) 1.01

Endoscopy in asymptomatic minidose aspirin consumers. Dig Dis Sci (2005) 0.98

Review article: aspirin and gastrointestinal bleeding. Aliment Pharmacol Ther (1994) 0.96

Trends in hospitalizations for peptic ulcer disease, United States, 1998-2005. Emerg Infect Dis (2010) 0.96

Recommended use of aspirin and other antiplatelet medications among adults--National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, United States, 2005-2008. MMWR Morb Mortal Wkly Rep (2012) 0.94

Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions. J Cardiovasc Pharmacol Ther (2006) 0.94

Death from undiagnosed peptic ulcer complications: a continuing challenge. Br J Surg (1988) 0.92

Risk of Upper Gastrointestinal Bleeding in a Cohort of New Users of Low-Dose ASA for Secondary Prevention of Cardiovascular Outcomes. Front Pharmacol (2010) 0.91

Long-term consequences of Helicobacter pylori eradication. Scand J Gastroenterol Suppl (1994) 0.89

Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease. World J Gastroenterol (2006) 0.89

Low-dose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol (2010) 0.88

Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: a case-control study. Scand J Gastroenterol (2007) 0.86

Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: facts or fancies? Eur J Intern Med (2010) 0.86

Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study. QJM (2010) 0.86

Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO]). Am J Cardiol (2009) 0.86

Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Thromb Haemost (2008) 0.86

Helicobacter pylori and autoimmune diseases. Oral Dis (2011) 0.86

Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. Eur Heart J (2011) 0.85

Clinical study of upper gastrointestinal bleeding associated with low-dose aspirin in Japanese patients. Hepatogastroenterology (2010) 0.85

An annotated algorithmic approach to upper gastrointestinal bleeding. Gastrointest Endosc (2001) 0.82

Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction. J Interv Cardiol (2005) 0.82

The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther (2006) 0.82

Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol (2011) 0.82

Aspirin's ability to induce intestinal injury in rats is dependent on bile and can be reversed if pre-associated with phosphatidylcholine. J Physiol Pharmacol (2011) 0.81

Short review about Helicobacter pylori infection in pediatric age: epidemiological and clinical findings, diagnosis, therapy and role of probiotics. Pediatr Med Chir (2012) 0.80

A clinician's guide to managing Helicobacter pylori infection. Cleve Clin J Med (2005) 0.79

From emergency room to morgue: deaths due to undiagnosed perforated peptic ulcers. Report of four cases with review of the literature. Am J Forensic Med Pathol (1994) 0.78

Acetylsalicylic acid/esomeprazole fixed-dose combination. Drugs Aging (2012) 0.77

Helicobacter pylori and NSAID gastropathy: an ambiguous association. Curr Rheumatol Rep (2001) 0.76

Anti-platelet therapy and managing ulcer risk. J Gastroenterol Hepatol (2012) 0.76